The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma.
 
Adi Diab
Consulting or Advisory Role - Celgene; CureVac; Nektar
Research Funding - Celgene (Inst); Idera (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar
 
Shah Rahimian
Employment - Idera
Travel, Accommodations, Expenses - Idera
 
Cara L. Haymaker
Research Funding - Idera; Nektar
 
Chantale Bernatchez
Employment - Lexicon (I)
Stock and Other Ownership Interests - Lexicon (I)
Consulting or Advisory Role - Lion Biotechnologies
Research Funding - Idera; Nektar
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Robert Hans Ingemar Andtbacka
Honoraria - Aduro Biotech; Amgen; Merck/Schering Plough; Novartis
Consulting or Advisory Role - Aduro Biotech; Amgen; Merck/Schering Plough; Novartis
Research Funding - Amgen (Inst); Idera (Inst); Oncolys BioPharma (Inst); OncoSec (Inst); Provectus (Inst); Takara Bio (Inst); Viralytics (Inst); X4 Pharma (Inst)
 
Marihella James
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Genoptix; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Joseph Markowitz
Consulting or Advisory Role - Idera; Newlink Genetics
Research Funding - Genoptix (Inst); Macrogenics (Inst); Morphogenesis (Inst); Reata Pharmaceuticals (Inst)
 
Ravi Murthy
No Relationships to Disclose
 
Igor Puzanov
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Merck
 
Montaser F. Shaheen
No Relationships to Disclose
 
Suzanne Swann
Employment - CSL Behring; Idera
Stock and Other Ownership Interests - GlaxoSmithKline; Idera